Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Darrigues L, Pierga JY, Bernard-Tessier A, Bièche I, Silveira AB, Michel M, Loirat D, Cottu P, Cabel L, Dubot C, Geiss R, Ricci F, Vincent-Salomon A, Proudhon C, Bidard FC. Darrigues L, et al. Among authors: ricci f. Breast Cancer Res. 2021 Mar 6;23(1):31. doi: 10.1186/s13058-021-01411-0. Breast Cancer Res. 2021. PMID: 33676547 Free PMC article.
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.
Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, Campone M, Trédan O, Ricci F, Alt M, Loirat D, Sablin MP, Paoletti X, Servois V, Le Tourneau C. Belin L, et al. Among authors: ricci f. Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666. Ann Oncol. 2017. PMID: 27993804 Free article. Clinical Trial.
[Cell cycle inhibitors in endocrine receptor positive breast cancer].
Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, Dieras V. Sablin MP, et al. Among authors: ricci f. Bull Cancer. 2017 Feb;104(2):114-122. doi: 10.1016/j.bulcan.2016.12.005. Epub 2017 Jan 23. Bull Cancer. 2017. PMID: 28126188 French.
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: ricci f. Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593830
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.
Dupain C, Masliah-Planchon J, Gu C, Girard E, Gestraud P, Du Rusquec P, Borcoman E, Bello D, Ricci F, Hescot S, Sablin MP, Tresca P, de Moura A, Loirat D, Frelaut M, Vincent-Salomon A, Lecerf C, Callens C, Antonio S, Franck C, Mariani O, Bièche I, Kamal M, Le Tourneau C, Servois V. Dupain C, et al. Among authors: ricci f. Mol Oncol. 2021 Jan;15(1):104-115. doi: 10.1002/1878-0261.12776. Epub 2020 Sep 15. Mol Oncol. 2021. PMID: 32750212 Free PMC article.
Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, Le Tourneau C. Basse C, et al. Among authors: ricci f. JCO Precis Oncol. 2018 Oct 19;2:PO.18.00048. doi: 10.1200/PO.18.00048. eCollection 2018. JCO Precis Oncol. 2018. PMID: 32914004 Free PMC article.
Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial.
Loap P, Loirat D, Berger F, Ricci F, Vincent-Salomon A, Ezzili C, Mosseri V, Fourquet A, Ezzalfani M, Kirova Y. Loap P, et al. Among authors: ricci f. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):436-440. doi: 10.1016/j.ijrobp.2020.09.032. Epub 2020 Sep 21. Int J Radiat Oncol Biol Phys. 2021. PMID: 32971187 Clinical Trial.
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breast.
Bièche I, Coussy F, El-Botty R, Vacher S, Château-Joubert S, Dahmani A, Montaudon E, Reyes C, Gentien D, Reyal F, Ricci F, Nicolas A, Marchio C, Vincent-Salomon A, Laé M, Marangoni E. Bièche I, et al. Among authors: ricci f. J Hematol Oncol. 2021 Sep 8;14(1):143. doi: 10.1186/s13045-021-01158-3. J Hematol Oncol. 2021. PMID: 34496925 Free PMC article.
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Vaflard P, Paoletti X, Servois V, Tresca P, Pons-Tostivint E, Sablin MP, Ricci F, Loirat D, Hescot S, Torossian N, Bello Roufai D, Kamal M, Borcoman E, Le Tourneau C. Vaflard P, et al. Among authors: ricci f. Drugs R D. 2021 Dec;21(4):399-406. doi: 10.1007/s40268-021-00362-3. Epub 2021 Sep 25. Drugs R D. 2021. PMID: 34562258 Free PMC article.
1,428 results